Latest1 information on COVID-19
©2022 Stanford Medicine
Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.
Not Recruiting
Trial ID: NCT01932060
Purpose
Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to
initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to
maintain adequate uterine tone after delivery. The study investigators aim to compare two
different infusion rates of oxytocin to assess the optimal infusion regimen for reducing
blood loss in women undergoing elective Cesarean delivery.
Official Title
Effects of Different Oxytocin Infusions on Blood Loss and Postpartum Hemoglobin Values in Patients Undergoing Elective Cesarean Delivery
Stanford Investigator(s)
Alex Butwick
Professor of Anesthesiology, Perioperative and Pain Medicine (OB)
Eligibility
Inclusion Criteria:
- Healthy pregnant patients with uncomplicated pregnancies:
- ASA (American Association of Anesthesiologists) class 1 or 2 patients.
- Singleton pregnancies.
Exclusion Criteria:
- ASA class 3 or 4 patients.
- Known drug allergy to intravenous oxytocin.
- Significant medical or obstetric disease.
- Known uterine abnormality.
- Known placental abnormality.
Intervention(s):
drug: Oxytocin Infusion
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Alexander J Butwick, F.R.C.A
650-736-8513